<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493984</url>
  </required_header>
  <id_info>
    <org_study_id>17.1114</org_study_id>
    <nct_id>NCT03493984</nct_id>
  </id_info>
  <brief_title>Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17</brief_title>
  <official_title>A Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Mitigate Insulin Resistance and Chronic Inflammation in Patients Diagnosed With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if substances contained in ginger or aloe plants, called&#xD;
      exosomes, will treat and improve the condition polycystic ovary syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator left the university prior to study approval, no patients enrolled&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glucose tolerance as measured by a glucose tolerance test</measure>
    <time_frame>Baseline, twelve weeks.</time_frame>
    <description>A glucose challenge test will be administered after initially obtaining a fasting serum glucose(baseline), then administering a 75 gram glucose load orally, then a serum glucose will be obtained 2 hours later. Serum glucose is measured in mg/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum insulin levels during a glucose tolerance test</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>Serum insulin levels in multi-international units per litre (mIU/L) will be measured at baseline and after 2 hours during a 2-hour glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Testosterone</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>Serum testosterone in ng/dL Changes in serum testosterone as measured in ng/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex hormone binding globulin</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>Changes in sex hormone binding globulin in nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool sample</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>Gut microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker cluster of differentiation 4 (CD4)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>CD4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker cluster of differentiation 8 (CD8)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>CD8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker Foxp3</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>Foxp3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker cluster of differentiation 11b (CD11b)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>CD11b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker cluster of differentiation 33 (CD33)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>CD33</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker F4/80</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>F4/80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker interleukin 10 (IL-10)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker interleukin 1b (IL-1b)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>IL-1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker tumor necrosis factor alpha (TNF-a)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>TNF-a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker interleukin 6 (IL-6)</measure>
    <time_frame>Baseline, twelve weeks</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ginger exosomes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aloe exosomes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ginger and aloe exosomes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ginger exosomes</intervention_name>
    <description>Naturally occurring plant exosomes from ginger</description>
    <arm_group_label>Ginger and aloe exosomes</arm_group_label>
    <arm_group_label>Ginger exosomes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aloe exosomes</intervention_name>
    <description>Naturally occurring plant exosomes from aloe</description>
    <arm_group_label>Aloe exosomes</arm_group_label>
    <arm_group_label>Ginger and aloe exosomes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Exosome placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-40 year&#xD;
&#xD;
          -  Patients must have a confirmed diagnosis of PCOS according to the Rotterdam Criteria.&#xD;
             At least 2 of the following 3 characteristics must be present: 1. Oligo-anovulation 2.&#xD;
             Clinical and/or biochemical signs of androgen excess and 3. Polycystic ovarian&#xD;
             morphology (PCOM) (defined by an increased number of small antral follicles [≥12&#xD;
             follicles that were &lt;10 mm in diameter] or an increased individual ovarian volume [&gt;10&#xD;
             cm3] in 1 or both ovaries. Disorders mimicking PCOS must also be excluded, including&#xD;
             thyroid dysfunction, hyperprolactinemia, late-onset congenital adrenal hyperplasia,&#xD;
             and ovarian or adrenal androgen-producing tumors.&#xD;
&#xD;
          -  Of all subjects screened patients must be informed of the investigational nature of&#xD;
             this study and give written informed consent in accordance with institutional and&#xD;
             federal guidelines.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Absence of life limiting medical conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Pregnancy&#xD;
&#xD;
               -  Known HIV&#xD;
&#xD;
               -  Patients receiving immunosuppressive drugs&#xD;
&#xD;
               -  Patients taking confounding medications such as sex steroids, infertility&#xD;
                  medications or insulin sensitizers or any medication deemed to alter glucose&#xD;
                  and/or insulin levels&#xD;
&#xD;
               -  Active malignancy in the last 5 years&#xD;
&#xD;
               -  Patients receiving any other investigational agent(s)&#xD;
&#xD;
               -  Ginger and/or aloe allergy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Bohler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

